Dilated cardiomyopathy (DCM) is a condition where the heart’s main pumping chamber, the left ventricle, stretches and enlarges, losing its ability to pump blood effectively. It affects roughly 1 in 250 people and is the most common type of cardiomyopathy, often leading to heart failure if untreated. The condition can develop at any age, though rates are highest in adults over 65 and in men.
What Happens Inside the Heart
In a healthy heart, the left ventricle contracts forcefully to push blood out to the rest of the body. In DCM, the muscle fibers of the ventricle weaken and the chamber begins to stretch. As the walls thin and the cavity grows larger, the heart compensates by trying to use the extra volume to maintain its output, a mechanism similar to stretching a rubber band further to get more snap. This works temporarily, but over time the stretched muscle loses its contractile strength.
At the cellular level, several things go wrong simultaneously. Individual heart muscle cells enlarge abnormally, some die off through a process called apoptosis, and scar tissue (fibrosis) fills in the gaps. The result is a heart that holds more blood but pushes less of it out with each beat. Doctors measure this efficiency as the ejection fraction, which is the percentage of blood pumped out per heartbeat. A normal ejection fraction is 55% or higher. DCM is typically diagnosed when it drops below 50%, alongside measurable enlargement of the left ventricle.
The enlargement also creates a vicious cycle. As the ventricle dilates, the tension on each muscle fiber increases, which means the heart has to work harder just to generate the same pumping force. This extra workload accelerates the damage and drives further stretching.
Common Symptoms
Many people with DCM have no symptoms in the early stages, which is why it sometimes goes undetected for years. As the heart’s pumping ability declines, the most common symptoms include fatigue, shortness of breath during physical activity or while lying flat, swelling in the legs, ankles, feet, or abdomen, and a reduced ability to exercise. Some people also notice chest discomfort or palpitations, a sensation of the heart beating fast, fluttering, or pounding.
These symptoms overlap heavily with heart failure in general, which makes sense: DCM is one of the leading causes of heart failure. The swelling occurs because the weakened heart can’t keep up with returning blood flow, causing fluid to back up into the lungs and body tissues. Breathlessness while lying down happens for the same reason, as gravity redistributes fluid toward the chest when you’re flat.
What Causes It
DCM has a wide range of causes, broadly split into genetic and acquired categories. In many cases, no specific cause is ever identified, and the condition is labeled “idiopathic.”
On the genetic side, mutations in genes that encode structural proteins of the heart muscle are the most common culprits. The single biggest contributor is a gene called TTN, which provides instructions for building titin, a massive protein that acts like a molecular spring inside heart muscle cells. Mutations in TTN account for 20 to 25% of genetic DCM cases. Other affected genes involve components of the sarcomere (the contractile unit of muscle) and the desmosome (the structure that holds heart cells together). If a first-degree relative has DCM, your own risk is significantly elevated.
Acquired causes include viral infections that inflame the heart muscle, long-term heavy alcohol use, exposure to certain toxins and chemotherapy drugs, autoimmune diseases, and hormonal disorders. Pregnancy can also trigger a form called peripartum cardiomyopathy, which develops in the final month of pregnancy or the months after delivery.
Alcohol and DCM
Alcohol-related cardiomyopathy deserves special mention because it is one of the most clearly reversible forms. Consuming roughly 80 grams of alcohol per day (about 5 to 6 standard drinks) for more than five years significantly raises the risk, though not everyone who drinks heavily develops it and there is no precise threshold known to be universally toxic to heart cells. The encouraging news is that people who stop drinking show measurable improvements in heart size and function, along with fewer hospitalizations. This makes early identification of alcohol as a contributing factor especially important.
How It’s Diagnosed
An echocardiogram, essentially an ultrasound of the heart, is the primary diagnostic tool. It allows doctors to measure the size of the left ventricle and calculate the ejection fraction in real time. The formal diagnostic criteria require both an ejection fraction below 50% and a left ventricle that is enlarged beyond the 95th percentile for the patient’s sex and height. Cardiac MRI can provide more detailed images and help identify scar tissue or inflammation within the heart muscle, which can point toward specific underlying causes.
Genetic testing is increasingly used, particularly when there’s a family history of DCM or when no other cause is apparent. Identifying a specific gene mutation can guide screening of family members who may carry the same variant but haven’t yet developed symptoms.
Treatment and Management
Treatment for DCM focuses on slowing disease progression, improving the heart’s pumping ability, and preventing complications like dangerous heart rhythms or blood clots. The current standard involves several categories of medication used in combination.
Drugs that block the renin-angiotensin system reduce the workload on the heart by lowering blood pressure and preventing harmful hormonal signaling that drives further remodeling. A newer combination drug that pairs this effect with an additional mechanism (inhibiting the breakdown of beneficial heart-protective proteins) has shown even greater benefits, improving survival, reducing hospitalizations, and actually reversing some of the structural damage in the ventricle.
Beta blockers slow the heart rate and reduce the force of each contraction, which sounds counterintuitive but actually protects the heart from the damaging effects of chronic overstimulation by stress hormones. Three specific beta blockers have been proven to reduce the risk of death in large clinical trials, and guidelines recommend starting at a low dose and gradually increasing. Even if symptoms don’t noticeably improve, long-term use is maintained because the mortality benefit persists.
A newer class of medications originally developed for diabetes, called SGLT2 inhibitors, has shown striking results in heart failure regardless of whether the patient has diabetes. In major trials, these drugs reduced the combined risk of cardiovascular death or heart failure hospitalization by about 25%, with a 30% reduction in hospitalizations specifically. The risk of cardiovascular death dropped by 18%, and the benefit appeared whether or not patients were diabetic.
Device Therapy for Advanced Cases
When medications alone aren’t enough, implantable devices can play a critical role. An implantable cardioverter-defibrillator (ICD) monitors the heart rhythm continuously and delivers a shock if it detects a life-threatening arrhythmia. DCM increases the risk of sudden cardiac death from irregular rhythms, and ICDs are considered for patients whose ejection fraction remains severely reduced despite optimal medication.
Cardiac resynchronization therapy (CRT) is an option for patients whose heart’s electrical system is also affected. In a healthy heart, the ventricles contract in a coordinated wave. In some DCM patients, this electrical timing becomes disrupted, causing different parts of the ventricle to contract out of sync. CRT uses a specialized pacemaker to restore that coordination. It’s typically considered when the electrical signal through the ventricles is delayed, measured as a QRS duration of 120 milliseconds or more on an electrocardiogram, particularly with a left bundle branch block pattern.
For patients with end-stage disease who don’t respond to medications or devices, heart transplantation remains an option, though donor availability limits its reach. Mechanical heart pumps can serve as a bridge to transplant or, in some cases, as a long-term solution.
Prognosis and What to Expect
The outlook for DCM has improved considerably with modern therapies, but it remains a serious condition. In one long-term study tracking patients over 15 years, the survival rate was 44% at 5 years, 39% at 10 years, and 34% at 15 years. These numbers reflect averages across a wide range of severity and underlying causes. Patients who respond well to medication, whose ejection fraction improves with treatment, or whose DCM has a reversible cause like alcohol tend to fare significantly better.
Age at diagnosis, the degree of ventricular enlargement, and the ejection fraction at the time of diagnosis all influence outcomes. In the United States, mortality rates are higher among older adults, men, and Black Americans, reflecting both biological and healthcare-access disparities. The condition accounts for a meaningful share of heart failure cases nationwide, with a period prevalence of roughly 118 per 100,000 people between 2017 and 2019.
For many people, DCM is a condition managed over years or decades rather than one with a rapid decline. Consistent use of guideline-directed medications, monitoring for rhythm disturbances, and addressing reversible factors like alcohol use or uncontrolled blood pressure can meaningfully change the trajectory.